953 related items for PubMed ID: 8640159
1. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[Abstract] [Full Text] [Related]
2. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
[Abstract] [Full Text] [Related]
3. High-dose chemotherapy and autologous peripheral blood progenitor cell transplant for the treatment of Hodgkin's disease.
Weaver CH, Schwartzberg L, Li W, Hazelton B, West W.
Bone Marrow Transplant; 1996 May 01; 17(5):715-21. PubMed ID: 8733687
[Abstract] [Full Text] [Related]
4. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma.
Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A, Coady-Lyons N, Zelenetz AD, Nimer SD.
Clin Cancer Res; 1998 Feb 01; 4(2):311-6. PubMed ID: 9516916
[Abstract] [Full Text] [Related]
5. High-dose therapy with peripheral blood progenitor cell support in patients with non-Hodgkin's lymphoma.
Haas R, Murea S, Goldschmidt H, Döhner H, Moos M, Witt B, Eugenhart R, Wannenmacher M, Hunstein W.
Stem Cells; 1995 Dec 01; 13 Suppl 3():28-35. PubMed ID: 8747986
[Abstract] [Full Text] [Related]
6. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
Bone Marrow Transplant; 1999 Feb 01; 23(3):235-41. PubMed ID: 10084254
[Abstract] [Full Text] [Related]
7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
Bone Marrow Transplant; 1999 Sep 01; 24(5):473-81. PubMed ID: 10482930
[Abstract] [Full Text] [Related]
8. Time-course of the recovery of cellular immune function after high-dose chemotherapy and peripheral blood progenitor cell transplantation for high-grade non-Hodgkin's lymphoma.
Scheid C, Pettengell R, Ghielmini M, Radford JA, Morgenstern GR, Stern PL, Crowther D.
Bone Marrow Transplant; 1995 Jun 01; 15(6):901-6. PubMed ID: 7581089
[Abstract] [Full Text] [Related]
9. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb 01; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
10. Mobilized peripheral blood progenitor cells (PBPC) in support of tandem cycles of high-dose chemotherapy (HDC).
Meisenberg BR, Miller WE, McMillan R.
Bone Marrow Transplant; 1996 Dec 01; 18(6):1087-93. PubMed ID: 8971377
[Abstract] [Full Text] [Related]
11. Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF.
Engelhardt M, Winkler J, Waller C, Lange W, Mertelsmann R, Henschler R.
Bone Marrow Transplant; 1997 Mar 01; 19(6):529-37. PubMed ID: 9181898
[Abstract] [Full Text] [Related]
12. A mononuclear cell dose of 3 x 10(8)/kg predicts early multilineage recovery in patients with malignant lymphoma treated with carmustine, etoposide, Ara-C and melphalan (BEAM) and peripheral blood progenitor cell transplantation.
Smith RJ, Sweetenham JW.
Exp Hematol; 1995 Dec 01; 23(14):1581-8. PubMed ID: 8542950
[Abstract] [Full Text] [Related]
13. Combination chemotherapy with mitoguazon, ifosfamide, MTX, etoposide (MIME) and G-CSF can efficiently mobilize PBPC in patients with Hodgkin's and non-Hodgkin's lymphoma.
Aurlien E, Holte H, Pharo A, Kvaløy S, Jakobsen E, Smeland EB, Kvalheim G.
Bone Marrow Transplant; 1998 May 01; 21(9):873-8. PubMed ID: 9613778
[Abstract] [Full Text] [Related]
14. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M, Al-Kgodary T.
Bone Marrow Transplant; 2006 Apr 01; 37(8):739-43. PubMed ID: 16501587
[Abstract] [Full Text] [Related]
15. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB.
Cancer Chemother Pharmacol; 2002 May 01; 49 Suppl 1():S13-20. PubMed ID: 12042984
[Abstract] [Full Text] [Related]
16. Long-term follow-up of patients with non-Hodgkin lymphoma following myeloablative therapy and autologous transplantation of CD34+-selected peripheral blood progenitor cells.
Witzens-Harig M, Heilmann C, Hensel M, Kornacker M, Benner A, Haas R, Fruehauf S, Ho AD.
Stem Cells; 2007 Jan 01; 25(1):228-35. PubMed ID: 17204607
[Abstract] [Full Text] [Related]
17. A phase 2 pilot study of pegfilgrastim and filgrastim for mobilizing peripheral blood progenitor cells in patients with non-Hodgkin's lymphoma receiving chemotherapy.
Russell N, Mesters R, Schubert J, Boogaerts M, Johnsen HE, Canizo CD, Baker N, Barker P, Skacel T, Schmitz N.
Haematologica; 2008 Mar 01; 93(3):405-12. PubMed ID: 18268285
[Abstract] [Full Text] [Related]
18. Autografting with peripheral blood stem cells mobilized by sequential interleukin-3/granulocyte-macrophage colony-stimulating factor following high-dose chemotherapy in non-Hodgkin's lymphoma.
Haas R, Ehrhardt R, Witt B, Goldschmidt H, Hohaus S, Pförsich M, Ehrlich H, Färber L, Hunstein W.
Bone Marrow Transplant; 1993 Dec 01; 12(6):643-9. PubMed ID: 7511017
[Abstract] [Full Text] [Related]
19. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
Biol Blood Marrow Transplant; 2004 Jun 01; 10(6):395-404. PubMed ID: 15148493
[Abstract] [Full Text] [Related]
20. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
Bone Marrow Transplant; 1998 Feb 01; 21(4):383-9. PubMed ID: 9509973
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
